WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 577545
CAS#: 211866-70-5
Description: PS-519 is a human tissue plasminogen activator and proteasome inhibitor.
MedKoo Cat#: 577545
Name: PS-519
CAS#: 211866-70-5
Chemical Formula: C12H19NO4
Exact Mass: 241.1314
Molecular Weight: 241.29
Elemental Analysis: C, 59.73; H, 7.94; N, 5.81; O, 26.52
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: LDP-519; LDP 519; LDP519; MLN-519; MLN 519; MLN519; PS-519; PS 519; PS519
IUPAC/Chemical Name: (1S,2R,5R)-5-((1S)-1-Hydroxy-2-methyl-propyl)-2-propyl-7-oxa-4-azabicyclo(3.2.0)heptane-3,6-dione
InChi Key: KMXHEXRPYSXLRN-JDVQERKKSA-N
InChi Code: 1S/C12H19NO4/c1-4-5-7-9-12(11(16)17-9,13-10(7)15)8(14)6(2)3/h6-9,14H,4-5H2,1-3H3,(H,13,15)/t7-,8+,9+,12-/m1/s1
SMILES Code: CCC[C@@H]1[C@@H]2OC(=O)[C@@]2(NC1=O)[C@@H](O)C(C)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 241.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1. Zhang L, Zhang ZG, Zhang RL, Lu M, Adams J, Elliott PJ, Chopp M. Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke. 2001 Dec 1;32(12):2926-31. doi: 10.1161/hs1201.100207. PMID: 11739997.
2. Vanderlugt CL, Rahbe SM, Elliott PJ, Dal Canto MC, Miller SD. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Autoimmun. 2000 May;14(3):205-11. doi: 10.1006/jaut.2000.0370. PMID: 10756082.
3. Shah IM, Lees KR, Pien CP, Elliott PJ. Early clinical experience with the novel proteasome inhibitor PS-519. Br J Clin Pharmacol. 2002 Sep;54(3):269-76. doi: 10.1046/j.1365-2125.2002.01638.x. PMID: 12236847; PMCID: PMC1874419.
